AUTOLUS THERAPEUTICS PLC Stock Price, News & Analysis

Autolus Therapeutics plc (Nasdaq: AUTL) has announced a strategic shift in its manufacturing operations for AUTO1, moving to a more cost-effective commercial supply strategy based in the UK. This change will utilize existing facilities and a new site to enhance its operational capacity. Additionally, the company has mutually terminated its lease in Rockville, MD, resulting in a cash payment and the cessation of lease obligations, which aims to further reduce costs.

Autolus Therapeutics plc (Nasdaq: AUTL) announced its operational and financial results for Q4 and FY 2020, showcasing a robust financial position after raising $131 million, enabling a cash runway into H1 2023. The company's AUTO1 program for adult B-ALL has shown promising results, with an 84% MRD-negative response in treated patients. However, net loss rose to $142.1 million in 2020, compared to $123.8 million in 2019. Management expects multiple clinical readouts in 2021 and 2022, including updates on AUTO1 and other CAR T therapies.

Autolus Therapeutics plc (Nasdaq: AUTL) announced that CEO Dr. Christian Itin will present at the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The event will feature one-on-one meetings with participants. A live audio webcast of the presentation will be available on Autolus’ investor relations page starting March 9 at 7:00 a.m. EST, with an archived replay accessible for 90 days. Autolus is focused on developing next-generation programmed T cell therapies aimed at treating various cancers.

Autolus Therapeutics plc (Nasdaq: AUTL) has successfully closed a public offering of 16,428,572 ADSs at a price of $7.00 each, raising approximately $115 million in gross proceeds. The offering included the full exercise of an option by underwriters for an additional 2,142,857 ADSs. J.P. Morgan and Wells Fargo Securities were the joint bookrunners for this transaction. The funds will support the development of Autolus' next-generation T cell therapies aimed at treating cancer, leveraging advanced programming technologies to improve efficacy against malignancies.

Autolus Therapeutics plc (Nasdaq: AUTL) has priced a public offering of 14,285,715 American Depositary Shares (ADSs) at $7.00 each, aiming to raise approximately $100 million. The offering is expected to close on February 12, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 2,142,857 ADSs.

This offering follows an effective shelf registration statement with the SEC, and all securities will be offered solely through a prospectus. Autolus is focused on developing advanced T cell therapies for cancer treatment.

Autolus Therapeutics plc (Nasdaq: AUTL) has announced a public offering of up to $100 million of its American Depositary Shares (ADSs). The offering, managed by J.P. Morgan and Wells Fargo Securities, may include an additional $15 million option for underwriters. This move is part of the company's strategy to support its development of next-generation T cell therapies for cancer. The offering is subject to market conditions, with no assurance regarding completion or terms.

Autolus Therapeutics (Nasdaq: AUTL) will disclose its Q4 2020 and full-year financial results on March 4, 2021, prior to U.S. market open. The company develops next-generation programmed T cell therapies and is expected to provide operational highlights during this release. A conference call will occur at 8:30 am ET, featuring a general business update and an opportunity for investors to engage. For those interested, access to the call will be available via the company’s website and dedicated phone lines.

Autolus Therapeutics plc (Nasdaq: AUTL) is prioritizing its CAR T cell therapy, AUTO1, targeting Adult Acute Lymphoblastic Leukemia (ALL). Key data from the AUTO1-AL1 study is expected in 2022. The company aims to partner its AUTO3 program and adjust its workforce by approximately 20%, anticipating annual cash savings of about $15 million. AUTO1 demonstrated promising results with a 52% event-free survival at 12 months. Autolus is advancing its pipeline focused on oncology, aiming for pivotal data and exploring additional B-cell malignancies.

Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in investor conferences in January 2021. Key events include:

• 11 January 2021 - Presentation at the H.C. Wainwright BioConnect 2021 Conference available on demand from 6:00 am ET.
• 13 January 2021 - Presentation at the 39th Annual J.P. Morgan Healthcare Conference at 9:10 am ET, with virtual meetings and a live webcast.

Archived replays will be accessible for 30 days post-conferences. Autolus develops innovative T cell therapies for cancer treatment.